Researchers conducted a comparison study of outcomes in patients with psoriatic arthritis treated with secukinumab, apremilast, and other biologic medications.
The prevalence of neuropathic-like pain was found to be high in patients with psoriatic arthritis, a condition that may be associated with higher disease activity and fibromyalgia.
A higher prevalence of NAFLD was observed among patients with psoriasis without arthritis compared with patients with psoriatic arthritis.
Open-label head-to-head trial compared efficacy and safety of ixekizumab with adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs.
MAXIMISE is an ongoing study evaluating the efficacy and safety of secukinumab 300 mg or 150mg in managing axial manifestations in patients with psoriatic arthritis.
Real-life data support the validity of switching from reference etanercept to SB4 for most patients with psoriatic arthritis.
Investigators assessed the risk for herpes zoster and provided recommendations regarding treatment in patients with psoriasis.
Anti-TNF-α agents have the same efficacy as ustekinumab, secukinumab, and ixekizumab in terms of dactylitis and enthesitis resolution.
Elevated C-reactive protein levels at baseline were associated with greater structural progression in psoriatic arthritis.
The presence of psoriatic nail dystrophy was linked to erosive damage at the distal interphalangeal joints.
The investigators sought to evaluate the risk for possible undiagnosed psoriatic arthritis in patients with psoriasis.
Investigators examined the grade of agreement between very low disease activity and Disease Activity Index for Psoriatic Arthritis remission.
Patients with PsA and severe skin manifestations had earlier onset and axial disease.
Recent data have linked inflammatory arthritis with hearing impairment.
Methotrexate with targeted escalation resulted in significant improvement in the skin, joint, dactylitis, enthesitis, and functional domains of PsA.